GeneThera, Inc.
GTHR · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.61 | -0.00 | 0.01 | -0.00 |
| FCF Yield | -1.05% | -1.84% | 0.11% | -147.70% |
| EV / EBITDA | -1.62 | -1.50 | -1.46 | -0.47 |
| Quality | ||||
| ROIC | 13.71% | 10.79% | 12.12% | 75.72% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.01 | 0.01 | -0.00 | 0.14 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -61.48% | -2,073.61% | 100.06% | -272.13% |
| Safety | ||||
| Net Debt / EBITDA | -0.81 | -1.10 | -1.11 | -0.37 |
| Interest Coverage | -453.69 | -21.89 | -25.86 | -33.29 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -5,604.27 | -5,604.27 | -1,915.21 | -8,825.74 |